secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020097
Event type: earnings
Sentiment:  neutral
Materiality: 0.35
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports Q1 net loss $19.1M; PC14586 trial advances
-------------------------------------------------------------

- Net loss Q1 2023 $19.1M vs $18.4M Q1 2022; cash & equivalents $229.4M.
- R&D expenses $15.1M (up from $11.8M) due to increased clinical costs for PC14586.
- Phase 1/2 PYNNACLE study of PC14586 ongoing; next update expected in 2H 2023.
- Enrollment commenced in combination arm of PC14586 with KEYTRUDA (pembrolizumab).
- Net cash used in operations $15.0M vs $18.0M in prior year period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017023020097/0000950170-23-020097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017023020097/pmvp-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer